Pulmonary Arterial Pressure Management Based on Oral Medicine for Pediatric Living Donor Liver Transplant With Portopulmonary Hypertension

• Published in: Transplantation proceedings 2018-11, Vol.50 (9), p.2614-2618
• Main Authors: Ueno, T., Hiwatashi, S., Saka, R., Yamanaka, H., Takama, Y., Tazuke, Y., Bessho, K., Kogaki, S., Yonekura, T., Okuyama, H.
• Format: Article
• Language: English
• Subjects: Administration, Oral; Adolescent; Child; Endothelin Receptor Antagonists - administration & dosage; Female; Humans; Hypertension, Portal - drug therapy; Hypertension, Pulmonary - drug therapy; Liver Transplantation - adverse effects; Liver Transplantation - methods; Living Donors; Male; Phosphodiesterase 5 Inhibitors - administration & dosage
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2018.03.068

Pediatric living donor liver transplantation (LDLT) in patients with advanced portopulmonary hypertension (PoPH) is associated with poor prognoses. Recently, novel oral medications, including endothelin receptor antagonists (ERAs), phosphodiesterase 5 (PDE5) inhibitors, and oral prostacyclin (PGI2) have been used to treat PoPH. Pediatric patients with PoPH who underwent LDLT from 2006 to 2016 were enrolled. Oral pulmonary hypertension (PH) medication was administered to control pulmonary arterial pressure (PAP). Four patients had PoPH. Their ages ranged from 6 to 16 years, and their original diseases were biliary atresia (n = 2), portal vein obstruction (n = 1), and intrahepatic portal systemic shunt (n = 1). For preoperative management, 2 patients received continuous intravenous PGI2 and 2 oral medications (an ERA alone or an ERA and a PDE5 inhibitor), and 2 received only oral drugs (an ERA and a PDE5 inhibitor). One patient managed only with intravenous PGI2 died. In the remaining 3 cases, intravenous PGI2 or NO was discontinued before the end of the first postoperative week. Postoperative medications were oral PGI2 alone (n = 1), an ERA alone (n = 1), or the combination of an ERA and a PDE5 inhibitor (n = 1). An ERA was the first-line therapy, and a PDE5 inhibitor was added if there was no effect. New oral PH medications were effective and safe for use in pediatric patients following LDLT. In particular, these new oral drugs prevent the need for central catheter access to infuse PGI2. •New oral pulmonary hypertension medications were effective for pediatric LDLT.•These medications were safe for use in pediatric patients following LDLT.•New oral drugs eliminate the need for central catheter access to infuse PGI2.